Skip to main content

Advertisement

Mycophenolate mofetil prevents the development of a clinical relapse in SLE patients at risk: an open pilot study

Article metrics

  • 1249 Accesses

Background

Systemic lupus erythematosus (SLE) is characterised by the presence of antibodies to double-stranded DNA (dsDNA). These antibodies are supposedly involved in the pathogenesis of SLE. Eighty percent of patients develop a clinical relapse within 10 weeks after a significant rise in anti-dsDNA level. This can be prevented by the administration of corticosteroids at the time of rise in anti-dsDNA. We hypothesise that administration of mofetil mycophenolate (MMF) will have similar effects without the side effects of corticosteroids.

Methods

SLE patients (n = 36) were followed monthly for a rise in levels of anti-dsDNA, defined as exceeding 125% of the level of the previous sample, and amounting at least 15 E/ml within a 4-month period. At the time of a rise patients started with 2000 mg MMF daily for a period of 6 months. Patients were monitored monthly for the occurrence of a clinical relapse and to assess serological activity and state of activation of CD4+, CD8+ and CD19+ lymphocyte subsets.

Results

In 10 patients a serological relapse was encountered. All patients started MMF and completed a 6 months study period without the occurrence of a clinical relapse. Side effects were minimal. Antibodies to dsDNA decreased during the study period (P < 0.001) associated with a decrease in activation of CD19+ lymphocytes. No difference in the state of activation of CD4+ or CD8+ lymphocyte subsets could be demonstrated.

Conclusion

Administration of MMF after a rise of antibodies to dsDNA prevents the occurrence of clinical relapses of SLE and is well tolerated.

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Bijl, M., Horst, G., Bootsma, H. et al. Mycophenolate mofetil prevents the development of a clinical relapse in SLE patients at risk: an open pilot study. Arthritis Res Ther 4, 104 (2002) doi:10.1186/ar439

Download citation

Keywords

  • Public Health
  • Corticosteroid
  • Systemic Lupus Erythematosus
  • Pilot Study
  • Systemic Lupus Erythematosus Patient